Dynasil Corp Of America · OTC:DYSL
Dynasil Corp Of America — Dynasil Corporation of America — Shareholder Meeting (February 2015)
37 slides from Dynasil Corp Of America's shareholder meeting presentation, Feb 26, 2015
Slide 1: Dynasil Corporation of America Annual Meeting of Stockholders
Dynasil Corporation of America Annual Meeting of Stockholders Peter Sulick, Chairman, President and CEO February 26, 2015
Slide 2: Forward-Looking Statements
Forward-Looking Statements The statements made in this presentation which are not statements of historical fact are forward looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements involve kn
Slide 3: Corporate Objectives - Ongoing
Corporate Objectives - Ongoing 1. Continued growth in Optics revenue through organic growth and opportunistic acquisitions to replace loss of Dynasil Products’ revenue and lower Contract Research revenue. 2. Conversion of job shop revenue stream across the Optics companies to more predictable, longe
Slide 4: Financial Summary FY 2014 vs. 2013
Financial Summary FY 2014 vs. 2013 Revenue decreased from $42.8 million in fiscal 2013 to $42.3 million in 2014. • Contract Research revenue remain essentially unchanged at $21.9 million. •Optics revenue increased 26%, from $15.6 million to $19.6 million. • Instruments revenue declined from $5.1 to
Slide 5: Fiscal Year 2014 Performance Highlights
Fiscal Year 2014 Performance Highlights Record Revenue at all Optics Operational Units. Corporate - Completed the sales of the Instruments products in the 1st quarter. Continued operation support for these sold products through mid-year and ultimate operational transfer to buyers by June, 2014. RMD
Slide 6: Debt
Debt $14,000,000 $12,000,000 $10,000,000 $8,000,000 $6,000,000 $4,000,000 $2,000,000 $- Santander Middlesex MCRC Total 6
Slide 7: Corporate Objectives - 2015
Corporate Objectives - 2015 1. Explore options for further external funding of Xcede Technologies for ongoing development of the tissue sealant technology. 2. Yield improvements across our Optics companies. 3. Continued commercial revenue growth in the double digit range. 4. Maintenance of 18+ month
Slide 8: FY 2015 1st Quarter Financial Summary
FY 2015 1st Quarter Financial Summary Revenue declined to $9.6 million from $10.7 million in the 1st quarter of 2014: •Contract Research revenue declined $1.2 million due to continuing reductions and slowdowns in government research grant funding. •Optics revenue increased $0.8 million as a result o
Slide 9: 1st Quarter 2015 – Performance Highlights
1st Quarter 2015 – Performance Highlights • Optics revenue of $4.9 million exceeded Research revenue of $4.7 million for the first time since RMD acquisition in 2008 • Sale of SPF Instrument at Optometrics (Gain of $185K) • Termination of EMF Defined Benefit Pension Plan (Loss of $355K) • Capital ex
Slide 10: RMD Highlights
RMD Highlights Dr. Kanai Shah February 2015 Business Sensitive
Slide 11: RMD Highlights FY-2014
RMD Highlights FY-2014 Celebrating 40th year of RMD! Closed FY14 at revenue of $21.9M Have current backlog of ~$33 M. Won R&D-100 Award on Plastic Scintillators CLYC commercial production started at RMD to support OEMs Transferring CsI:Tl film technology to EMF 6 Patents Awarded and 14
Slide 12: RMD Crystal Growth
RMD Crystal Growth Tl6SeI4 LiSr2I5:Eu CsI 4” NaI SrI2 Beta Battery 1.5” SrI2 LiInSe2 Cs2 6LiLaB6: Ce CLYC 3” CLYC 1” 1.5” 2” Kyropoulos Growth Business Sensitive 12
Slide 13: Plastics and Polycrystalline Materials
Plastics and Polycrystalline Materials Fabricated 3” diameter plastic scintillators 45 x 45 x 5.5mm GLuGAG Ceramic LCI: Li3Cs2I5:Tl, Li3Cs2I5:Eu LNI: LixNa1-xI:Tl, LixNa1-xI:Eu films 2” DPA crystal Plastic Scintillator Gamma Ray Spectrometer Business Sensitive 13
Slide 14: Nuclear and X-Ray Imaging
Nuclear and X-Ray Imaging CLYC RadCam II Combined gamma-neutron RadCam image NASA Mars Lander Probe Braided Copper Wire 1 200 0.9 400 0.8 600 0.7 800 0.6 1000 0.5 1200 0.4 1400 0.3 1600 Cooling pipe in a nuclear 0.2 1800 LCI-LNI neutrons 0.1 2000 0 power plant in Japan IC chip 200 400 600 800 1000 1
Slide 15: Photonic Structures and Coatings
Photonic Structures and Coatings 14000 LSO-grease-PMT LSO-air-PMT 12000 LSO-PhC1-glass-grease-PMT 10000 8000 #1, +9.0% gain 6000 4000 Grease 2000 (without GRIN) 0 100 200 300 400 500 600 700 Channel number IBSC K2CsSb photocathode compound Business Sensitive 15
Slide 16: RMD in Space
RMD in Space ARA-APDs AF Space Weather Space telescope calibrator SrI2 SSPM gamma ray telescope Crystal growth on the Mars probe International Space Station Business Sensitive 16
Slide 17: Detectors & Instruments
Detectors & Instruments Avalanche Photodides Prototype Beta Probe CLYC/SSPM 11x11 TlBr Array SSPM array Pipe Scanning Robot Business Sensitive 17
Slide 18: Xcede – February 2015
Dynasil Corporation of America Xcede – February 2015
Slide 19: Xcede Technologies Introduction
Xcede Technologies Introduction Xcede Technologies has developed a game changing hemostat sealant patch which differentiates itself due to its adhesive capability and ability to be used on high pressure arterial bleeding. 19
Slide 20: Xcede Technologies’ Value Proposition
Xcede Technologies’ Value Proposition •Superior technology •Large and growing market-$5.5 Billion •Extremely low manufacturing costs •Alone in its ability to be used on very high pressure bleeding •Predictable and known development pathway •Partnership with Mayo Clinic •Industry with acquisition mom
Slide 21: Our Solution: The Xcede Patch Version 2.0
Our Solution: The Xcede Patch Significant research and development has resulted in multiple formations of the patch (version 1.0 and version 2.0) resulting in its present configuration of a preformed 4”x4” two layer patch consisting of a fibrin mesh with proprietary adhesive backing. Version 2.0 H
Slide 22: Current Xcede Technologies’ Team
Current Xcede Technologies’ Team Management Board of Directors Vic Schmitt Dave Talen - CEO 20 years of marketing, sales and general management Peter Sulick experience in the Medical Device Industry. Sarah Combs Management positions at Scimed Life Systems, Integ, Urologix, Spinetech and Timm Med
Slide 23: Strategy
Strategy • Launch the Xcede patch first in Europe and then in the US with initial indication for General Surgery in mild to moderate bleeding. • First in human clinical trial and pilot data • FDA pivotal trials • Partner with large, established company for distribution outside the US • In house dire
Slide 24: Hemostat/Sealant Markets are Large and Growing
Hemostat/Sealant Markets are Large and Growing • Broad indication creates robust opportunity to capture both the hemostats and the fibrin and other sealants markets • $5.5 billion global combined market in 2015 • CAGR 8.69% 2010 - 2017 Global Hemostats, Fibrin & Other Sealants 8 7 Billions USD 6 5 4
Slide 25: Problem: Every Sealant Out There Has Limitations
Problem: Every Sealant Out There Has Limitations There are more than 30 companies worldwide with hemostats or sealants, driving a global market of $5.5 billion. Yet none of the current products are optimal, as they do not address complex high pressure bleeding, are difficult to prepare or take a lon
Slide 26: And For Some Procedures There is Nothing
And For Some Procedures There is Nothing Tissue Bleeding Vascular Anastomotic Bleeding Fibrin Gels Powdered Complex Fibrin • Bone • Organ Injuries • Avulsion Flowables wounds Nothing Aqueous Thrombin Synthetic Sealants Simple • Skin • Tissue flaps • Graft Mechanical Patches surfaces Hemostats Mild M
Slide 27: The Xcede Patch Works Better Everywhere
The Xcede Patch Works Better Everywhere …. Tissue Bleeding Vascular Anastomotic Bleeding Complex Even here • Bone • Organ Injuries • Avulsion wounds Xcede Patch Simple works in all indications • Skin • Tissue flaps • Graft surfaces Mild Moderate Low pressure High pressure 27
Slide 28: And Outperforms the Competition
And Outperforms the Competition Characteristic Xcede Patch Evarrest™ Tachosil™ Surgeon hold time 15 seconds 3 minutes 3 minutes Stops severe arterial bleeding XX No Thrombin XX Flexible to fit complex wounds X Long shelf life at room temp X X X Effective on junctional wounds X X High burst resistanc
Slide 29: Video
Video https://youtu.be/4VeuOOKGD9g 29
Slide 30: Xcede Patch Pre-Clinical Work to Date
Xcede Patch Pre-Clinical Work to Date Animal Studies 65 acute animals; 18 survival animals: vascular sealing, intramuscular and subcutaneous implant Preclinical studies have shown superior performance in many applications: Spleen and liver hemostasis Partial nephrectomy hemostasis Lung sea
Slide 31: Intellectual Property Portfolio – Protection from Competition
Intellectual Property Portfolio – Protection from Competition Filing Patent name Summary Status date Composition – components of Tissue Patch Allowed 10/4/2012 patch and primer Systems and Methods for the Engineering – steps to make patch Published 10/4/2012 fabrication of tissue patches and primer
Slide 32: An Industry with Momentum - Acquisition Activity
An Industry with Momentum-Hemostat/Sealant Market is Flush with Acquisition Activity Company/Product Partner Date Status at acquisition Acquisition Amount RecoThrom The Medicines 2012/ FDA approved $105 million collaboration fee, $10 Company 2014 million option with purchase price based on Net Reven
Slide 33: Xcede Technologies’ Funding History
Xcede Technologies’ Funding History 2015 2014 Explore Angel funding options for 2013 of $2 million in further external the form of funding. Xcede Technologies convertible formed. Mayo notes 2011 – 2013 becomes a Dynasil Shareholder Biomedical (DBM) funds Tissue Sealant technology. 33
Slide 34: Dynasil’s Strategic Objectives for Xcede
Dynasil’s Strategic Objectives for Xcede •Attract long-term biotech investors to Xcede to fund its future. •Preserve Dynasil’s equity position/investment in Xcede, so that Dynasil’s stockholders share in the upside. •De-consolidate Xcede from Dynasil so Xcede’s losses are no longer on Dynasil’s fina
Slide 35: Summary
Summary • Xcede has game changing technology with unique hemostatic and sealant properties • Superb team and partners • Partnership with Mayo Clinic • Experienced management • Large and growing market • Robust IP position • Active acquisition landscape in Hemostat and Sealant market 35
Slide 36: Questions
> Dynasil Questions
Slide 37: Dynasil Corporation of America Annual Meeting of Stockholders
Dynasil Corporation of America Annual Meeting of Stockholders Peter Sulick Chairman, President and CEO February 26, 2015
Dynasil Corporation of America — Shareholder Meeting (February 2015) on 6ix